Hosted on MSN16d
EC approves GSK’s Jemperli-chemo combo for endometrial cancerThe European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or ...
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback